A new CAR T cell therapy targeting ovarian cancer
An allogeneic gamma/delta armored Dual-Targeting CAR with Split Costimulatory Domains to Target Epithelial Ovarian Carcinoma
This study is testing a new type of CAR T cell therapy for women with ovarian cancer that uses special immune cells to better target the cancer and includes a safety feature to help protect patients from side effects.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Luminary Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10921643 on NIH RePORTER |
What this research studies
This research focuses on developing a novel CAR T cell therapy specifically designed to treat epithelial ovarian carcinoma. It utilizes an allogeneic gamma/delta T cell platform combined with a split CAR approach, which targets two different antigens to minimize the risk of antigen escape. The therapy also includes an inducible suicide switch to enhance patient safety and reduce side effects. By addressing the challenges of solid tumors, this innovative treatment aims to improve T cell persistence and effectiveness in combating cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with epithelial ovarian carcinoma who have not responded to standard treatments.
Not a fit: Patients with hematological malignancies or those not diagnosed with solid tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with epithelial ovarian carcinoma.
How similar studies have performed: While CAR T cell therapies have shown success in hematological cancers, this approach for solid tumors is relatively novel and has not been extensively tested.
Where this research is happening
Minneapolis, United States
- Luminary Therapeutics, INC. — Minneapolis, United States (Active)
Researchers
- Principal investigator: Hickenlooper, Samuel — Luminary Therapeutics, INC.
- Study coordinator: Hickenlooper, Samuel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.